基于组合赋权-TOPSIS的中国新冠疫苗专利竞争力分析

Analysis of Patent Competitiveness of COVID-19 Vaccine in China Based on Combination Empowerment- TOPSIS

关键词:  组合赋权-TOPSIS  新冠疫苗  专利竞争力

Key words:  combination empowerment-TOPSIS  COVID-19 vaccine  patent competitiveness

摘要:

目的 依据专利数据探究中国主要新冠疫苗技术的发展水平和竞争情况。方法 对中国5种主要新冠疫苗进行专利竞争力评价指标体系的构建，并依据检索到的专利数据进行层次分析法-熵权法组合赋权和TOPSIS竞争力分析。结果 中国现有的5种主要新冠疫苗中，重组亚单位疫苗、重组病毒载体疫苗和核酸疫苗专利竞争力相对较强，灭活疫苗和减毒疫苗相对较弱。结论 中国新冠疫苗专利市场和技术格局逐渐趋于成熟，研发机构应当在确保疫苗安全性的基础上聚焦技术热点、致力创新研发，探索技术发展新出路。

Abstract:

OBJECTIVE To explore the development level and competition of major COVID-19 vaccine technologies in China based on patent data. METHODS The patent competitiveness evaluation index system of five major COVID-19 vaccines in China was constructed, and the analytical hierarchy process-entropy weight combination empowerment method and TOPSIS competitiveness analysis were carried out based on the retrieved patent data. RESULTS Among the five existing major COVID-19 vaccines, recombinant subunit vaccine, recombinant virus vector vaccine and nucleic acid vaccine had relatively strong patent competitiveness, while inactivated vaccine and attenuated vaccine were relatively weak. CONCLUSION China’s COVID-19 vaccine patent market and technology pattern are gradually becoming mature, and research and development institutions should focus on technology hotspots, devote themselves to innovative research and development, and explore new ways of technological development on the basis of ensuring vaccine safety.